Eli Lilly To Present New Data Across Its Cardiometabolic Health Portfolio At The Annual Meeting of the European Association for the Study of Diabetes; Results From TRIUMPH-2 Showed Investigational Triple Hormone Receptor Agonist Retatrutide Delivered Substantial Weight Loss And A1C Improvements In Obesity And Type 2 Diabetes